Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 35.2% in February

Avenue Therapeutics, Inc. (NASDAQ:ATXIGet Free Report) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 59,700 shares, a decline of 35.2% from the February 13th total of 92,200 shares. Currently, 3.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 376,300 shares, the short-interest ratio is currently 0.2 days.

Avenue Therapeutics Trading Up 9.7 %

Shares of Avenue Therapeutics stock opened at $0.85 on Friday. The company has a 50-day moving average of $1.44 and a two-hundred day moving average of $1.93. Avenue Therapeutics has a 12-month low of $0.72 and a 12-month high of $13.13. The stock has a market cap of $1.74 million, a PE ratio of 0.05 and a beta of -0.29.

Institutional Trading of Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Boothbay Fund Management LLC purchased a new position in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXIFree Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 41,089 shares of the company’s stock, valued at approximately $82,000. Boothbay Fund Management LLC owned about 2.00% of Avenue Therapeutics as of its most recent SEC filing. 17.34% of the stock is owned by hedge funds and other institutional investors.

Avenue Therapeutics Company Profile

(Get Free Report)

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.

Further Reading

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.